Mostrar el registro sencillo del ítem

dc.rights.licenseopenen_US
dc.contributor.authorNGUYEN, Joanne Thanh-Tâm
dc.contributor.authorBARBET-MASSIN, Marie-Amélie
dc.contributor.authorPUPIER, Emilie
dc.contributor.authorLARROUMET, Alice
dc.contributor.authorBOSC, Laurène
dc.contributor.authorMICHELET, Marie
dc.contributor.authorMONSAINGEON-HENRY, Maud
hal.structure.identifierNeurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB]
dc.contributor.authorGATTA-CHERIFI, Blandine
dc.date.accessioned2025-05-26T13:46:17Z
dc.date.available2025-05-26T13:46:17Z
dc.date.issued2024
dc.identifier.issn1662-4025en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/206718
dc.description.abstractEnIntroduction: Extreme obesity (BMI ≥50 kg/m2) is a complex pathology to treat. One of the complications of extreme obesity is massive localized lymphedema (MLL), due to compromised lymphatic drainage. There is a lack of literature guiding the medical management of these conditions. Case Presentation: We present a 43-year-old male who was admitted to our specialized obesity center for weight management. His initial weight was 255 kg and BMI was 93.7 kg/m2. He suffered from massive multifocal lymphedema of his left leg. He was bedridden due to his condition and malnourished, as shown by multiple vitamin deficiencies. The patient received care from our multidisciplinary team including nurses, dieticians, physical therapists, and psychologists. Treatment with semaglutide was started in hospital and continued at home. The maximal dose used was 1 mg/week but decreased during follow-up to 0.25 mg/week to avoid malnutrition. Protein and nutritional supplements were added. At 28 weeks of therapy, the patient had lost 40 kg or 15.7% of his total body weight. His lymphedema decreased; he had lost at least 16 cm of his left thigh circumference. He was able to walk again and regain autonomy of his daily activities of living. Conclusion: Semaglutide can be effective in patients with extreme obesity, with the support of a multidisciplinary team in a specialized obesity center. It can also help decrease MLL. More data are needed to guide medical treatment of patients with extreme obesity and MLL. © 2024 The Author(s). Published by S. Karger AG, Basel.
dc.language.isoENen_US
dc.rightsAttribution-NonCommercial 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/us/*
dc.subject.enSemaglutide
dc.subject.enGLP1-RA
dc.subject.enObesity
dc.subject.enLymphedema
dc.title.enSemaglutide Treatment in a Patient with Extreme Obesity and Massive Lymphedema: A Case Report
dc.title.alternativeObes Factsen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1159/000540241en_US
dc.subject.halSciences du Vivant [q-bio]/Neurosciences [q-bio.NC]en_US
dc.identifier.pubmed39250902en_US
bordeaux.journalObesity Factsen_US
bordeaux.page641 – 645en_US
bordeaux.volume17en_US
bordeaux.hal.laboratoriesNeurocentre Magendie - U1215en_US
bordeaux.issue6en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamPhysiopathologie de l'équilibre énergétique et obésitéen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-05085357
hal.version1
hal.date.transferred2025-05-26T13:46:20Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
dc.rights.ccCC BY-NCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Obesity%20Facts&rft.date=2024&rft.volume=17&rft.issue=6&rft.spage=641%20%E2%80%93%20645&rft.epage=641%20%E2%80%93%20645&rft.eissn=1662-4025&rft.issn=1662-4025&rft.au=NGUYEN,%20Joanne%20Thanh-T%C3%A2m&BARBET-MASSIN,%20Marie-Am%C3%A9lie&PUPIER,%20Emilie&LARROUMET,%20Alice&BOSC,%20Laur%C3%A8ne&rft.genre=article


Archivos en el ítem

Thumbnail
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem